Get News Story – Page 3689 – Just another WordPress site

CAR-T Therapy Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, and other

DelveInsight’s, “CAR-T Therapy Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 252+ pipeline drugs in the CAR-T Therapy pipeline landscape. It covers the CAR-T Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the CAR-T Therapy Pipeline Report

DelveInsight’s CAR-T Therapy pipeline report depicts a robust space with 200+ active players working to develop 252+ pipeline therapies for CAR-T Therapy treatment.
The leading companies working in the CAR-T Therapy Market include CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
Promising CAR-T Therapy Pipeline Therapies in the various stages of development include Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.
December 2023: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for PHE885. A Phase 2 Study of PHE885, B-cell Maturation Antigen (BCMA)- Directed CAR-T Cells in Adult Participants With Relapsed and Refractory Multiple Myeloma.
December 2023: Allogene Therapeutics announced a study of Phase 1 clinical trials for ALLO-501, ALLO-647, Fludarabine and Cyclophosphamide. The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
November 2023: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd announced a study of Phase 1 clinical trials for CD19 CAR-T cells. This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
November 2023: Chongqing Precision Biotech Co., Ltd announced a study of Phase 1 clinical trials for CEA CAR-T cells. This trial is an open-label, single-arm clinical study. The main purpose is to verify the safety and efficacy of CAR-T cell preparations in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended dose and infusion scheme of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignant tumors.

Request a sample and discover the recent advances in CAR-T Therapy Treatment Drugs @ CAR-T Therapy Pipeline Report

In the CAR-T Therapy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

CAR-T Therapy Overview

Chimeric Antigen Receptors (CARs), also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor.

Find out more about CAR-T Therapy Treatment Drugs @ Drugs for CAR-T Therapy Treatment

CAR-T Therapy Emerging Drugs Profile

CT053: Carsgen Therapeutics
Descartes-08: Cartesian Therapeutics
ALLO-501A: Allogene Therapeutics
CTX110: CRISPR Therapeutics
IMPT 314: ImmPACT Bio
ALLO-715: Allogene Therapeutics

CAR-T Therapy Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the therapies for CAR-T Therapy. The CAR-T Therapy companies which have their CAR-T Therapy drug candidates in the most advanced stage, i.e. Registered include, Carsgen Therapeutics.

DelveInsight’s CAR-T Therapy pipeline report covers around 252+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

CAR-T Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

CAR-T Therapy Pipeline Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn more about the emerging CAR-T Therapy Pipeline Therapies @ CAR-T Therapy Clinical Trials Assessment

Scope of the CAR-T Therapy Pipeline Report

Coverage- Global
CAR-T Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
CAR-T Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
CAR-T Therapy Companies- CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
CAR-T Therapy Pipeline Therapies- Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.

Dive deep into rich insights for new drugs for CAR-T Therapy treatment, Visit @ CAR-T Therapy Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
CAR-T Therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
CAR-T Therapy– DelveInsight’s Analytical Perspective
Late Stage Products (Registered)
CT053: Carsgen Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Descartes-08: Cartesian Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ALLO-715: Allogene Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
ACLX 003: Arcellx
Drug profiles in the detailed report…..
Inactive Products
CAR-T Therapy Key Companies
CAR-T Therapy Key Products
CAR-T Therapy- Unmet Needs
CAR-T Therapy- Market Drivers and Barriers
CAR-T Therapy- Future Perspectives and Conclusion
CAR-T Therapy Analyst Views
CAR-T Therapy Key Companies
Appendix

For further information on the CAR-T Therapy pipeline therapeutics, reach out @ CAR-T Therapy Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/fabry-disease-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Therapy Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, and other

Simplify Paralleling Switchgear Updates in ASCO Power Webinar

Attendees will learn the value of renewing instead of replacing paralleling switchgear to achieve significant benefits.

Florham Park, N.J., USA – December 4, 2023 – Paralleling switchgear can be upgraded to expand functionality and increase savings without disrupting operations. On December 11, 2023, power professionals can join ASCO Power Technologies Business Development Manager Dominic Magni and Regional Project Manager Aaron Samuels in a webinar titled How to Design Power Control System Modernization Projects.

The discussion will help power professionals aid their clients in executing projects more quickly at a lower cost. Hosted jointly by ASCO Power Technologies and Consulting Specifying Engineer, this webinar will be led by ASCO’s experts. Attendees can ask presenters about critical backup power topics and applications.

“Join us as we provide insight into the capabilities and benefits of Power Control System Modernization and Project Execution,” says Business Development Manager Dominic Magni. “Specifiers will learn how to streamline projects, drive savings, enhance sustainability, and maintain continuity. Attendees will gain valuable insights that help facilities thrive in this ever-evolving energy landscape.”

By attending the event, professionals will:

Learn the basics of power control system modernization.
Know when to specify a power control system upgrade or modification.
Review drawing markup packages and sequences of operation options.
Understand component-, door-, and panel-level modernization options.
Review examples and case studies.

To learn the benefits of power control system modernization, register here.

Visit the ASCO Power events page to find upcoming events and keep up with the latest in backup power. Subscribe to the ASCO Power newsletter to receive industry news and company updates in your inbox.

About ASCO Power Technologies 

ASCO Power Technologies has provided power reliability solutions for more than 125 years. As part of Schneider Electric, ASCO Power offers industry-leading power source and load management solutions that maximize resilience and sustainability to solve emerging power challenges. The firm designs, manufactures, services, and supports automatic transfer switches, power control systems, and critical power management appliances. ASCO products serve mission-critical functions in data centers, healthcare facilities, telecommunication networks, commercial buildings, and industrial operations.

Media Contact
Company Name: ASCO Power Technologies
Contact Person: Laurence Grodsky
Email: Send Email
Phone: + 1 973 307 7352
Address:160 Park Avenue
City: Florham Park
State: New Jersey
Country: United States
Website: https://www.ascopower.com/us/en/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Simplify Paralleling Switchgear Updates in ASCO Power Webinar

Glioblastoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, and others.

DelveInsight’s, “Glioblastoma Pipeline Insight 2023” report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Glioblastoma Pipeline Report

DelveInsight’s Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment.
The leading companies working in the Glioblastoma Market include Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
Promising Glioblastoma Pipeline Therapies in the various stages of development include Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.
November 2023: Boston Scientific Corporation announced a study of early Phase 1 clinical trials for TheraSphere GBM. The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
November 2023: Chimeric Therapeutics announced a study of Phase 1 clinical trials for CHM-1101 CAR-T cells. This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive).
November 2023: In8Bio Inc. announced a study of Phase 1 & 2 clinical trials for Autologous genetically modified gamma-delta T cells. A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma.
November 2023: Novartis Pharmaceuticals announced a study of Phase 1 clinical trials for Temozolomide and Radiotherapy. A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent.

Request a sample and discover the recent advances in Glioblastoma Treatment Drugs @ Glioblastoma Pipeline Outlook Report

In the Glioblastoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Glioblastoma Overview

Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations.

Find out more about Glioblastoma Treatment Landscape @ Drugs for Glioblastoma Treatment

Glioblastoma Emerging Drugs Profile

Enzastaurin: Denovo BioPharma
Tofacitinib: Pfizer
VT1021: Vigeo Therapeutics
Varlilumab: Celldex Therapeutics
Debio 0123: Debiopharm
PRT3645: Prelude Therapeutics

Glioblastoma Pipeline Therapeutics Assessment

There are approx. 195+ key companies which are developing the therapies for Glioblastoma. The Glioblastoma companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo BioPharma.

DelveInsight’s Glioblastoma pipeline report covers around 210+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Glioblastoma Pipeline Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn more about the emerging Glioblastoma Pipeline Therapies @ Glioblastoma Clinical Trials Assessment

Scope of the Glioblastoma Pipeline Report

Coverage- Global
Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
Glioblastoma Pipeline Therapies- Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.

Dive deep into rich insights for new drugs for Glioblastoma treatment, Visit @ Glioblastoma Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Glioblastoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Glioblastoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Enzastaurin: Denovo BioPharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Varlilumab: Celldex Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
PRT3645: Prelude Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
ELC-401: Elicera Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Glioblastoma Key Companies
Glioblastoma Key Products
Glioblastoma- Unmet Needs
Glioblastoma- Market Drivers and Barriers
Glioblastoma- Future Perspectives and Conclusion
Glioblastoma Analyst Views
Glioblastoma Key Companies
Appendix

For further information on the Glioblastoma pipeline therapeutics, reach out @ Glioblastoma Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, and others.

NK Cell Therapy Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Synimmune, and others

DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the NK Cell Therapy Pipeline Report

DelveInsight’s NK Cell Therapy pipeline report depicts a robust space with 100+ active players working to develop 185+ pipeline therapies for NK Cell Therapy treatment.
The leading companies working in the NK Cell Therapy Market include ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.
Promising NK Cell Therapy Pipeline Therapies in the various stages of development include Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.
November 2023: Precision Biotech Taiwan Corp. announced a study of Phase 1 & 2 clinical trials for donor-derived NK cell infusion. A Phase Ι & IIa, Open-label Study to Evaluate Safety and Efficacy of the Combination Therapy of Allogeneic PB103 and Standard Cancer Treatment in the IIIB/IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Patients.
November 2023: NKGen Biotech Inc. announced a study of Phase 1 clinical trials for SNK02. A Phase 1, Open-Label, Dose Escalation Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Participants With Pathologically Confirmed Cancer Refractory to Conventional Therapy.

Request a sample and discover the recent advances in NK Cell Therapy Treatment Drugs @ NK Cell Therapy Infection Pipeline Report

In the NK Cell Therapy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Natural Killer (NK) cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

NK Cell Therapy Overview

Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm.

Find out more about NK Cell Therapy Treatment Landscape @ Drugs for NK Cell Therapy Treatment

NK Cell Therapy Emerging Drugs Profile

NKTR-214: Nektar therapeutics
Monalizumab: Innate Pharma
Bemarituzumab: Five Prime Therapeutics
ALT 803: ImmunityBio
CellProtect: XNK Therapeutics
K-NK002: Kiadis Pharma
NK-92: ImmunityBio
WU-NK-101: Wugen
Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
ALECSAT: CytoVac

NK Cell Therapy Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Natural Killer (NK) cell therapy. The NK Cell Therapy companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.

NK Cell Therapy Segmentation:-

DelveInsight’s NK Cell Therapy pipeline report covers around 185+ products under different phases of clinical development like

Late-stage products (Phase III and
Mid-stage products (Phase II and
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

NK Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion
Intradermal
Intramuscular
Intranasal
Intravaginal
Oral
Parenteral
Subcutaneous
Topical.
Molecule Type

NK Cell Therapy Pipeline Products have been categorized under various Molecule types such as

Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule
Product Type

Learn more about the emerging NK Cell Therapy Pipeline Therapies @ NK Cell Therapy Clinical Trials Assessment

Scope of the NK Cell Therapy Pipeline Report

Coverage- Global
NK Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
NK Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
NK Cell Therapy Companies- ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.
NK Cell Therapy Pipeline Therapies- Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.

Dive deep into rich insights for new drugs for NK Cell Therapy treatment, Visit @ NK Cell Therapy Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Natural Killer (NK) cell therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
NKTR-214: Nektar therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
CellProtect: XNK Therapeutics
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
Drug profiles in the detailed report…..
Inactive Products
Natural Killer (NK) cell therapy Key Companies
Natural Killer (NK) cell therapy Key Products
Natural Killer (NK) cell therapy- Unmet Needs
Natural Killer (NK) cell therapy- Market Drivers and Barriers
Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
Natural Killer (NK) cell therapy Analyst Views
Natural Killer (NK) cell therapy Key Companies
Appendix

For further information on the NK Cell Therapy pipeline therapeutics, reach out @ NK Cell Therapy Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NK Cell Therapy Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Synimmune, and others

North America Confectionery Market Surge: USA’s $28.2 Billion Boom in 2023

“North America Confectionery Market 2024-2032”

The expansion of North America’s confectionery market is propelled by the rising demand for sugary treats like gums, jellies, chocolates, and snack bars. This trend is largely due to the diverse range of flavors, shapes, and sizes available in these products.

The latest research from Expert Market Research, titled ‘North America Confectionery Market Share, Size, Analysis and Forecast 2024-2032′, offers a comprehensive review of the confectionery market in North America. This report evaluates the market through various segments, including types of confectioneries and key regional markets within North America.

This study tracks current industry trends and their influence on the overall market. It also examines the dynamics of the market, focusing on crucial demand and price indicators. Additionally, the report provides an analysis of the market utilizing both SWOT analysis and Porter’s Five Forces models to give a detailed perspective on the market’s structure and competitive landscape.

The key highlights of the report include:

Market Overview (2018-2032)

Forecast CAGR (2024-2032): 1.9% (United States Confectionery Market)

North America Confectionery Market Share

The North America confectionery market is a dynamic and significant sector within the global confectionery industry. Characterized by a diverse range of products, including chocolates, candies, gums, and snack bars, this market enjoys a substantial share due to its large consumer base with varied preferences.

Get a Free Sample Report with Table of Contents@ https://bityl.co/MjIB

The United States, being a key player, dominates the market in terms of both production and consumption, followed closely by Canada. Market share is influenced by factors like innovative product launches, growing consumer interest in premium and artisanal confectioneries, and a steady demand for traditional sweets.

The rise in health-conscious consumers is also steering the market towards sugar-free and organic options, further diversifying the market share within this region. The integration of online retail and e-commerce platforms has expanded market reach, making confectionery products more accessible to a wider audience, thereby enhancing market penetration and share in North America.

The North American confectionery market is experiencing growth, primarily fueled by the rising popularity of sugar-rich treats such as gums, jellies, chocolates, and snack bars, among others. This trend is largely due to the wide array of available flavors, shapes, and sizes of these confectionery items.

Looking ahead, the market is expected to see further growth, spurred by an increasing demand for confectioneries during special occasions and festivals like Christmas and Easter, which typically boost confectionery sales. Additionally, the robust presence and strategic expansion efforts of leading market players in the United States are anticipated to be key drivers in propelling the market forward in the upcoming years.

Read Full Report with Table of Contents@ https://bityl.co/MjID

Defining North America’s Confectionery Sector and Key Categories

Confectionery items are snack products characterized by their high sugar and carbohydrate content. These treats are crafted to delight consumers’ taste buds, often being associated with enjoyment and indulgence. Typically consumed during special events or festive occasions, confectionery products also feature a variety of food colorings and innovative flavors, adding to their appeal.

On the basis of type, the market can be segmented into:

Chocolate

White

Milk

Dark

Non-Chocolate

Gums & Mints

The major countries in the North America confectionery market include:

United States of America

Canada

Trends in the Confectionery Market of North America

Market trends indicate significant business prospects in the United States and Canada, bolstered by government backing. This support is nurturing advancements in product innovation and research and development, focused on crafting superior confectionery items featuring unique flavors and ingredients. Additionally, the rise of vegan confectionery options, particularly those with reduced sugar and gluten-free attributes, is expected to fuel market growth shortly. Furthermore, the swift growth of the e-commerce sector in this region is set to enhance the accessibility and appeal of confectionery products to a broader audience, including new potential customers.

North America Confectionery Market Growth

The North America Confectionery Market is experiencing robust growth, driven by diverse consumer preferences and innovative product offerings. Key factors fueling this expansion include the rising popularity of premium and artisanal confectioneries, a growing inclination towards health-conscious choices like organic and sugar-free options, and the increased demand for unique and exotic flavors. The United States, as a major market contributor, continues to set trends with its wide variety of confectionery products, while Canada’s market is also showing considerable growth. Additionally, the integration of e-commerce and digital marketing strategies has broadened the reach of confectionery products, making them more accessible to a wider audience and thus contributing to the overall growth of the confectionery market in North America.

North America Confectionery Market Forecast

The forecast for the North America Confectionery Market points towards continued growth and evolution. This expansion is anticipated to be driven by several key factors, including ongoing innovation in flavors and product formats, a greater emphasis on health-conscious and ethical options like organic, sugar-free, and vegan confectioneries, and the impact of evolving consumer preferences. The United States is expected to maintain its dominance in the market, with ongoing product development and marketing strategies tailored to diverse consumer groups.

Additionally, the market is likely to see a boost from the growing influence of e-commerce and digital marketing, making confectionery products more accessible to a broader audience. The Canadian market is also projected to show significant growth, contributing to the overall expansion of the sector in North America. Furthermore, seasonal and festive sales, along with the introduction of innovative and niche products, are expected to play a crucial role in driving market dynamics during the forecast period.

Key Market Players

The major players in the market are:

The Hershey Company

Nestle S.A (Nestle USA)

Mars Inc.

Ferrero SpA

Mondelez International, Inc.

Chocoladefabriken Lindt & Sprüngli AG

The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

Read Our Top Trending Related Reports:

South Korea Honey Market: https://bityl.co/MjHi

Mexico Frozen Fruits Market: https://bityl.co/MjHj

Malaysia Cordial Drink Market: https://bityl.co/MjHk

India Online Food Delivery Market: https://bityl.co/MjHl

South Korea Vegan Chocolate Market: https://bityl.co/MjHm

About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analysis provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today’s competitive market.

Don’t miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organisation’s future success by acquiring one of our Expert Market Research reports today.

Media Contact
Company Name: Expert Market Research
Contact Person: Matt Johnson
Email: Send Email
Phone: +1-415-325-5166
Address:30 North Gould Street
City: Sheridan
State: Wyoming
Country: United States
Website: https://www.expertmarketresearch.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: North America Confectionery Market Surge: USA\’s $28.2 Billion Boom in 2023

Unveiling the Future: South Korea’s Artificial Intelligence Market (2024-2032)

“South Korea artificial intelligence market 2024-2032”

The South Korea artificial intelligence market size reached a staggering USD 1,011.04 million in 2023, signaling a new era of technological advancements in the country. This dynamic market is on a trajectory to expand at a CAGR of 15.3% between 2024 and 2032, culminating in a projected value of USD 3,614.26 million by 2032. Such growth is indicative of South Korea’s commitment to integrating AI in various sectors, making it a pivotal player in the global AI landscape.

The ‘South Korea Artificial Intelligence Market Size, Share, Forecast and Analysis (2024-2032)’ by Expert Market Research offers a comprehensive review of the artificial intelligence sector in South Korea. This detailed report evaluates the market through various segments, including product and service types, technological advancements, and end-user applications.

This study provides insights into the most recent developments within the market and their wide-ranging effects. Additionally, it examines both the current demand for artificial intelligence in South Korea and key factors influencing pricing and demand. The report further explores the market dynamics using tools such as SWOT analysis and Porter’s Five Forces Model, offering a strategic perspective on the market’s growth and challenges.

The key highlights of the report include:

Market Overview (2018-2032)

Historical Market Size (2023): USD 1,011.04 Million
Forecast CAGR (2024-2032): 15.3%
Forecast Market Size (2032): USD 3,614.26 million

In the past decade, South Korea’s artificial intelligence (AI) sector has experienced a remarkable surge, marked by the filing of over 6000 AI-centric patents. Looking ahead, the AI market in South Korea is poised for further expansion, particularly in the commercialization of AI products and services. The adoption of pay-as-you-go AI solutions is gaining momentum, enabling businesses to experiment with AI features without substantial initial investments. This increasing embracement of AI technologies is anticipated to be a significant driving force for the market’s growth in the near future.

Get a Free Sample Report with Table of Contents@ https://bityl.co/MjEe

The South Korea AI market is finding fertile ground for growth across various sectors, including security, manufacturing, healthcare, and automotive. These industries present attractive prospects for the market’s expansion. Furthermore, the government’s dedicated initiatives to bolster the digital infrastructure of the country are also playing a crucial role in advancing the AI market.

In recent times, technologies like data digitalization, natural language processing, and machine learning have seen rapid advancement and proliferation. The growing need for sophisticated text analytics and the advancements in machine-to-machine technology are central to driving the growth of South Korea’s AI market.

Defining South Korea’s Artificial Intelligence Sector and Its Key Components

Artificial intelligence (AI) is a branch of computer science focused on creating systems or machines that display human-like intelligence. This involves the ability to analyze, make decisions, and learn from previous experiences. The progress in AI technology has enabled the integration of human-like cognitive functions in machines, encompassing skills like reasoning, generalizing from existing data, and deriving insights from past interactions.

Read Full Report with Table of Contents@ https://bityl.co/MjEY

On the basis of product and service, the market is segmented into:

Hardware

Software

Service

Based on technology, the market is classified into:

Machine Learning

Natural Language Processing

Others

On the basis on end use, the market is categorised into:

Security

Media and Advertising

Retail

Automotive

Healthcare

Manufacturing

Others

Trends in the South Korean Artificial Intelligence Market

In the South Korean artificial intelligence (AI) market, several key trends are shaping its future. Notably, there’s an uptick in investment and research by major companies focusing on the commercialization of AI products and services for both domestic and international markets. The burgeoning information technology sector, along with a heightened adoption of cloud-based solutions, is anticipated to further propel market growth. These solutions are critical for enhancing operational efficiency and processing large data sets.

Moreover, advancements in 5G technology and a growing demand for virtual assistants are expected to boost the need for AI in South Korea. The automotive industry is also witnessing a surge in the use of AI, particularly with the increasing popularity of self-driving vehicles, which in turn is stimulating market growth.

In the realm of media and advertising, AI is increasingly used to improve streaming services, particularly with the rising popularity of OTT platforms. This trend is likely to positively influence the growth of South Korea’s AI market. In healthcare, the escalating incidence of chronic diseases is driving the adoption of AI for remote patient monitoring and disease identification, further contributing to the sector’s expansion.

Leading Participants in the South Korean Artificial Intelligence Market

The prominent companies featured in the South Korea artificial intelligence market report include:

Samsung Electronics Co. Ltd

SK Telecom Co., Ltd.

KT Corporation

LG Corporation

Kakao Enterprise

Microsoft Corporation

Google LLC

Amazon Web Services, Inc.

Riiid, Inc.

Additional key players

The report provides an in-depth analysis of various aspects of these market participants, including their market shares, production capacities, facility turnarounds, and expansions. It also delves into their recent investments, as well as mergers and acquisitions, alongside other noteworthy developments in the market.

Read Our Top Trending Reports:

South Korea Honey Market: https://bityl.co/MjED

South Korea Hybrid Cars Market: https://bityl.co/MjEC

South Korea Luxury Goods Market: https://bityl.co/MjEB

South Korea Functional Water Market: https://bityl.co/MjEI

South Korea Health Supplements Market: https://bityl.co/MjEE

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Unveiling the Future: South Korea\’s Artificial Intelligence Market (2024-2032)

HAVOK Consulting Highlights Exclusive Savings on Custom Websites and Web Services

HAVOK Consulting is a premier business consulting company. In a recent update, the company highlighted exclusive savings on custom websites and web services.

Brandon, FL – In a website post, HAVOK Consulting highlighted exclusive savings on custom websites and web services.

The team noted that one of the key savings that HAVOK Consulting is offering is a discounted rate on custom web design and development. HAVOK Consulting is now offering $1,000 OFF Web development Boca Raton and design in Boca Raton, FL, or any web service $5K or more from HAVOK Consulting. The focus is on web development. Enticing business owners of all sizes or anyone in Boca Raton, FL to schedule a FREE consultation to explore how HAVOK Consulting can help them with their web needs.

The experts mentioned that HAVOK Consulting is also offering savings on their website maintenance services. Keeping a website up-to-date and running smoothly is a time-consuming task, especially for those without technical knowledge in web design Boca Raton. HAVOK Consulting takes on this responsibility for their clients, ensuring that their websites are always functioning at their best. And with the current savings, clients can now take advantage of these services at a lower cost.

Another notable offering from HAVOK Consulting is their search engine optimization (SEO) services, which are designed to improve a website’s search engine ranking and overall online visibility. With the majority of consumers using search engines to find products and services, having a strong SEO strategy is essential for businesses. HAVOK Consulting’s team of experts is skilled in the latest SEO techniques and passionate about increasing their clients’ online visibility.

The professionals added that HAVOK Consulting offers discounts on their e-commerce website services. With the rise of online shopping, having functional and well-designed e-commerce custom websites Boca Raton is essential for any business looking to sell their products or services online. HAVOK Consulting provides customized e-commerce solutions to meet the unique needs of each client, and with the current savings, businesses can now take advantage of these services at a reduced cost.

About HAVOK Consulting

HAVOK Consulting is a leading business and marketing consulting firm serving Boca Raton, FL that specializes in developing high-performing, responsive websites. We help you secure a confident approach to marketing, product positioning, and sales while establishing a strong visual presence. HAVOK Consulting is the firm that helps you go above and beyond what was thought to be possible and exceed expectations when it comes to growth, marketing, and sales.

Media Contact
Company Name: HAVOK Consulting
Contact Person: Matt Genna
Email: Send Email
Phone: (833) 373-7627
Address:1032 E Brandon Blvd, #7286
City: Brandon
State: FL, 33511
Country: United States
Website: https://havokconsulting.com/services/boca-raton-web-development-services/

1-Decene Market, Size, Share, Trends, Forecast To 2031

“1-Decene Market”

1-Decene Market By Application (Poly Alpha Olefin, Polyethylene, Detergent Alcohols, Others)- Growth, Share, Opportunities & Competitive Analysis, 2023 – 2031

The market for 1-Decene is growing steadily, propelled by its diverse applications in numerous industries. During the period between 2023 and 2031, the market revenue is expected to grow at a promising CAGR of 6.5%. 1-Decene, also known as decene-1, is a ten-carbon alpha-olefin hydrocarbon. It is produced predominantly through the oligomerization of ethylene or the Fischer-Tropsch synthesis method. Due to its extensive spectrum of applications, the 1-Decene industry is expanding. It functions as a fundamental building block in the synthesis of numerous chemical compounds and polymers. 1-Decene is used extensively in the production of linear low-density polyethylene (LLDPE), which has packaging, film, and coating applications. Due to its superior properties such as flexibility, impact resistance, and chemical resistance, the demand for LLDPE is increasing. This contributes to the expansion of the 1-Decene market. Additionally, 1-Decene is employed in the production of synthetic lubricants and surfactants. Compared to conventional lubricants, synthetic lubricants offer superior performance, greater temperature stability, and enhanced efficiency. The expanding automotive and industrial sectors are driving the demand for synthetic lubricants, thereby boosting the 1-Decene market’s expansion. In addition, 1-Decene is used in the production of detergent alcohols, which are essential ingredients in a variety of cleansing and personal care products. The growing awareness of hygiene and the rising demand for personal care products are driving the demand for detergent alcohols and, in turn, the 1-Decene market. The 1-Decene market is also influenced by technological advancements, research and development activities, and the rising demand for sustainable and environmentally beneficial products. To meet the growing demand for 1-Decene and its derivatives, manufacturers are concentrating on devising efficient and economical production processes.

The increasing demand for polyethylene and polyalphaolefins (PAOs) drives the 1-Decene market. Polyethylene, especially linear low-density polyethylene (LLDPE), is utilized extensively in a variety of industries, including packaging, automotive, and construction. LLDPE is appropriate for applications such as films, coatings, and molded products due to its excellent flexibility, impact resistance, and chemical resistance. The rising global population and rising consumer demand for packaged products are major contributors to the expansion of the polyethylene market, thereby driving demand for 1-Decene as a feedstock. The International Energy Agency (IEA) predicts that the global demand for polyethylene will increase by 3.8% per year on average between 2021 and 2026. In addition, 1-Decene-derived polyalphaolefins (PAOs) are extensively used as synthetic lubricants due to their superior performance characteristics. PAOs are superior to conventional mineral oils in terms of thermal stability, oxidation resistance, and viscosity index. Increasing demand for high-performance lubricants in automotive, industrial, and aerospace applications is propelling the expansion of the PAO market, which in turn is increasing demand for 1-Decene.

Increasing demand for detergent alcohols is a significant market driver for 1-Decene. Detergent alcohols, which are predominantly derived from 1-Decene, are essential components in the production of cleaning products, laundry detergents, and personal care items. The global demand for these products is driven by the increasing awareness of hygiene, the expanding population, and the changing consumer lifestyles. The global detergent alcohol market was valued at over $4 billion in 2020 and is anticipated to experience rapid expansion in the years to come. It is anticipated that the demand for 1-Decene as a basic material for detergent alcohols will increase in tandem with the demand for these products.

Browse for the report at: https://www.acutemarketreports.com/report/1-decene-market

Significantly propelling the 1-Decene market are technological advancements and process innovations. Continuous investments are made in R&D by manufacturers to enhance production processes, increase yield, and reduce costs. Innovations in catalyst technology, process design, and reactor systems have enhanced the purity and quality of 1-Decene production. These innovations have increased production efficiency and decreased environmental impact. For instance, the development of metallocene catalysts has enhanced the selectivity and yield of 1-Decene during oligomerization. These technological advancements and process innovations contribute to the expansion of the 1-Decene market by allowing manufacturers to meet the rising demand and increase overall production efficiency.

Due to the volatility of raw material prices and the possibility of supply constraints, the 1-Decene market is hampered significantly. Ethylene, which is derived from crude hydrocarbons or natural gas, is the primary raw material used to manufacture 1-Decene. Changes in the price of crude oil, geopolitical tensions, and supply-demand imbalances can result in significant price fluctuations for ethylene. These price fluctuations have a direct effect on the production costs of 1-Decene, reducing the profitability of manufacturers and possibly resulting in higher prices for end consumers. In addition, supply constraints in the ethylene market can be caused by production interruptions, transportation problems, or changes in feedstock availability. These supply constraints can potentially disrupt the 1-Decene supply chain, resulting in production and delivery delays. The oil price disruptions witnessed in 2020 due to the COVID-19 pandemic and geopolitical events are an illustration of the impact of volatile raw material prices. These shocks led to a substantial decline in crude oil prices, disrupting the chemical industry and impacting the profitability of market participants in the 1-Decene sector. Therefore, the volatility in raw material prices and potential supply constraints pose a significant restraint for the 1-Decene market, necessitating that manufacturers closely monitor and manage their raw material sourcing strategies to mitigate the effects of these obstacles.

Access Free Sample Copy From https://www.acutemarketreports.com/request-free-sample/139674

The application segment of the 1-Decene market includes numerous industries, such as poly alpha olefin (PAO), polyethylene, and detergent alcohol. Among these applications, poly alpha olefin (PAO) is anticipated to have the highest CAGR from 2023 to 2031, and it also generated a significant amount of revenue in 2022. Due to their superior performance characteristics, such as thermal stability, oxidation resistance, and viscosity index, PAOs, which are derived from 1-Decene, are extensively used as synthetic lubricants. Increasing demand for high-performance lubricants in automotive, industrial, and aerospace applications is driving the expansion of the PAO market, thereby contributing to the 1-Decene market’s revenue. In addition, polyethylene, particularly linear low-density polyethylene (LLDPE), is an important use of 1-Decene. Due to its flexibility, impact resistance, and chemical resistance, LLDPE is widely employed in numerous industries, including packaging, automotive, and construction. The increasing global population and demand for packaged products are driving the demand for polyethylene, which has a positive impact on the revenue of the 1-Decene market. Additionally, detergent alcohols, which are essential components of cleaning products, laundry detergents, and personal care products, are an important application of 1-Decene. Demand for detergent alcohols is anticipated to increase, thereby contributing to the growth of the 1-Decene market, as global hygiene awareness and the demand for personal care products continue to rise. Other applications, such as plastics, additives, and specialty chemicals, contribute to market revenue as well.

Due to the presence of major manufacturing centers, rising industrialization, and robust demand for chemicals and polymers, Asia-Pacific held the largest revenue share of the market in 2022. Demand for 1-Decene as a key raw material in the production of polyethylene and polyalphaolefins (PAOs) is driven by the region’s thriving automotive, packaging, and consumer products industries. In addition, the region is experiencing accelerated urbanization, rising disposable income levels, and a rising population, all of which contribute to the demand for end-use products containing 1-Decene, such as lubricants, plastics, and detergents. In addition, Asia-Pacific is anticipated to demonstrate the highest CAGR from 2023 to 2031. The demand for 1-Decene is driven by the region’s expanding industrial base, favorable government policies, and investments in infrastructure development. Moreover, China, India, and Japan are significant contributors to the growth of the Asia-Pacific market, as their manufacturing sectors are expanding rapidly and they are experiencing an increase in demand for chemicals and polymers.

Other Popular Reports: https://www.acutemarketreports.com/category/chemicals-market

The 1-Decene market is characterized by intense competition between a number of prominent global participants. These businesses concentrate on strategic initiatives to strengthen their market presence, expand their product lines, and meet the changing needs of their customers. Exxon Mobil Corporation, Chevron Phillips Chemical Company LLC, INEOS Group Holdings S.A., Shell Chemicals, and Sasol Limited are among the market leaders in 1-Decene. These key players implement a variety of strategies to obtain a competitive advantage and achieve sustainable growth. The expansion of production capacities is one of the primary strategies for meeting the rising demand for 1-Decene. To expand their production capabilities and geographic reach, businesses invest in facility expansions, new plant constructions, and partnerships with local actors. In addition, the emphasis on sustainability and environmental responsibility has acquired considerable importance in the 1-Decene market. To reduce their carbon footprint, businesses are increasingly employing eco-friendly manufacturing processes and exploring renewable feedstocks. They actively engage in research and development of bio-based alternatives and invest in technologies that allow for more sustainable production of 1-Decene. To capitalize on emerging opportunities and maintain their market positions, market leaders will continue to focus on expanding their production capacities, investing in research and development, and investigating strategic partnerships.

Media Contact
Company Name: Acute Market Reports, Inc.
Contact Person: Chris Paul
Email: Send Email
Phone: US/Canada: +1-855-455-8662, India: +91 7755981103
Address:90 Church St, FL 1 #3514, New York, NY 10008, USA
City: New York
State: New York
Country: United States
Website: www.acutemarketreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: 1-Decene Market, Size, Share, Trends, Forecast To 2031

Reviving Authentic ’80s Soundscapes: Dress to Kill Reignites the Era of Analog Synth Pop

Dress To Kill’s melodic and enriching Electronic Pop music echoes a unique and characteristic mix of 80’s nostalgia

Dress To Kill, an iconic Pop duo originally hailing from Liverpool, delivers a distinct and genuine sound straight from the golden era of 80’s pop culture.

In 1984, Andi Cooper and Jim Doran founded Dress To Kill, drawing inspiration from iconic bands like Fashion, Depeche Mode, Japan, and Gary Numan. Their musical journey began without modern-day conveniences like sequencers or computers. Utilizing synths such as the Moog Rogue and Roland Juno 6, coupled with drum machines, they crafted their signature sound.

Starting with their debut performance in Liverpool’s The System nightclub in 1985, Dress To Kill instantly captivated audiences, reminiscent of acclaimed bands like Ultravox, New Order, and The Human League. However, it was in 1987, amidst life’s changes, that they ventured into a 12×12 bedroom armed with a Fostex 260 4-track porta studio, synths, and a drum machine.

For 37 years, their music remained unheard, yet now, through collaboration with Ottawa recording engineer Jason Jaknunas, Dress To Kill’s original recordings are undergoing a revival. Rather than re-recording, the songs are receiving professional mixing while maintaining their authentic ’80s essence.

Their tracks, including “The Showman,” “Twilight,” and “Watching the Ships Burn,” bring back the energy and emotion of the ’80s electronic pop scene. The duo invites listeners to stream or purchase their music, promising to infuse contemporary audiences with the genuine spirit of Dress to Kill once more.

ABOUT

Dress To Kill’s musical saga originated from an ’80s analog synth retro new wave, created within the confines of a 12×12 bedroom. Initially recorded on a 4-track cassette porta studio, their music now enters the digital era. Andi and Jim’s shared musical influences and their quest to establish a unique fusion of melodic electronic pop lay the foundation for Dress To Kill.

After 37 years, the music has resurfaced, thanks to Ottawa recording engineer Jason Jaknunas, who helps Dress To Kill reintroduce their authentic ’80s sound. As the duo unveils this musical time capsule, they invite audiences to rediscover the magic of ’80s pop with a contemporary twist.

LINKS

Facebook: https://www.facebook.com/profile.php?id=100076110662579

Instagram: https://www.instagram.com/dresstokillband/

Twitter: https://twitter.com/home?logout=1699221601742

YouTube: https://www.youtube.com/channel/UC7ptqVc-3WIMTVaEFICnHnA

Spotify: https://artists.spotify.com/c/artist/5GEB3KUReOTapT3dFlz3Kx/profile/about

SoundCloud: https://soundcloud.com/andi-cooper-337055949

Reverbnation: https://www.reverbnation.com/dresstokill7?profile_view_source=header_icon_nav

Media Contact
Company Name: Dress To Kill
Contact Person: Andi Cooper
Email: Send Email
Phone: 800-983-1362
City: Ottawa
State: Ontario
Country: Canada
Website: https://www.facebook.com/profile.php?id=100076110662579

China’s first national-level offshore wind power research and test inspection base begins construction.

On December 1, China’s first national-level offshore wind power research and test inspection base (hereinafter referred to as “offshore wind power test base”) began construction in Fujian. This is an important measure to deeply implement Xi Jinping’s new era of socialism with Chinese characteristics and the spirit of the 20th National Congress of the Communist Party of China, adhere to innovation-driven development, implement the strategy of strengthening enterprises through science and technology, and promote a leapfrog development from Made in China to Created in China, and then to China leading. It is also a significant breakthrough in creating original technology hubs, promoting clean and low-carbon energy transformation, and aiding the construction of a new type of power system and new energy system.

Picture: Cai Hao

The offshore wind power test base is a major project in China’s “14th Five-Year Plan.” The project is jointly invested and constructed by the State Grid Corporation of China, China Huadian Corporation, and the Power Construction Corporation of China, with plans to be fully operational by 2024. The base aims to establish an internationally first-class offshore wind power research platform, test platform, and exchange and cooperation platform. It is dedicated to creating an industrial ecosystem integrating “technology research, testing and certification, equipment manufacturing, construction and installation, and operation and maintenance.” This will fill the gap in China’s lack of a large-power, full-size ground test platform, with the technical capability of the test equipment aiming to be the world’s best. Once completed, the base will further enhance China’s research and testing capabilities in offshore wind power equipment, accelerate the breakthrough in key technologies and grid-connection technologies for offshore wind power equipment, and significantly contribute to improving China’s wind power technology level and equipment manufacturing capacity. This will promote the high-quality development of the wind power industry and help achieve China’s “dual carbon” goals.

In recent years, the State Grid Corporation of China has continuously strengthened its research and testing capabilities in offshore wind power equipment, building on its existing onshore wind power test and verification capacity. The newly started offshore wind power test base is an important part of the National Key Laboratory for Renewable Energy Grid Integration. It includes an onshore testing center and a test wind farm, with its main functions being the full-size ground testing of wind turbine units with six degrees of freedom loading, ultra-large capacity complex grid simulation, ultra-long blade biaxial high-frequency loading tests, and scientific research.

The onshore testing center is located in the Jiangyin Industrial Park in Fuqing City, Fujian Province, near the Jiangyin Port Terminal and adjacent to the Three Gorges Wind Power Industrial Park. The main construction includes a 25-megawatt six degrees of freedom loading, full-size ground test platform, and a 150-meter-class blade test platform. The test wind farm is planned to have 6 onshore test positions and 20-40 offshore test positions, with the first batch of 20 offshore test positions located in the offshore area of Changle, Fujian Province.

1. The construction of the offshore wind power test base will enhance the technological innovation level of China’s wind power industry, seize the high ground in world energy technology, and help achieve high-level scientific and technological self-reliance and self-strengthening. Since 2020, China’s offshore wind power has developed rapidly, with wind power units entering the era of large capacity. As of the end of September this year, the cumulative installed capacity of offshore wind power nationwide has reached 31.89 million kilowatts. Compared with existing test and verification platforms at home and abroad, once completed, the offshore wind power test base will cover all offshore wind power performance test and verification capabilities specified in the latest IEC and relevant national standards. Its test platform towing capacity, loading capacity, and grid simulation capabilities will be the world’s best, capable of conducting tests on the world’s largest-capacity wind turbines and the longest blades, as well as offshore wind turbine unit full-frequency impedance scanning tests, which are currently not possible internationally. Once operational, the test base, integrating simulation analysis, operational testing, characteristic evaluation, and technological R&D, will conduct empirical research on large-capacity offshore wind turbines, research on grid-friendly wind power integration technology, and digital twin research on the full characteristics of single offshore wind turbines and stations. It will lead in international standard formulation and tackle key core technologies in offshore wind power, significantly enhancing China’s basic research and testing capabilities in offshore wind power.

2. The construction of the offshore wind power test base will facilitate the deep integration of the industrial and innovation chains, promoting the upgrade of the offshore wind power industry and driving the advancement of industrial foundations and the modernization of the industrial chain. Once operational, the base will further improve the offshore wind power technological innovation and service system, providing comprehensive services such as scientific research, testing verification, and exchange and sharing for Chinese offshore wind power equipment manufacturers, research institutions, operators, and other upstream and downstream industry chain entities. This will promote the formation of a complete industrial ecosystem, accelerate product R&D upgrades, enhance the independent R&D capability and international competitiveness of China’s electrical equipment manufacturing industry, and improve the resilience and safety levels of the industrial and supply chains.

As a hub of original technology, the base will help accelerate the R&D of new wind power equipment technologies, overcome the bottlenecks in manufacturing large-capacity offshore wind turbine units and large-size blades, and enhance the level of Chinese offshore wind power equipment manufacturing technology. This will boost the high-quality development of the offshore wind power industry.

3. The construction of the offshore wind power test base will facilitate the development of a new type of power system and a new energy system, serving the transition to clean and low-carbon energy and helping to achieve the “dual carbon” goals. Water, wind, and solar clean energy sources have gradually become the main energy sources for China’s construction of a new type of power system. They are the main force in supporting the decarbonization of the power system and then driving the entire energy system and society towards carbon neutrality. Currently, Fujian Province has developed a general layout where clean energy accounts for half of the energy mix and a full range of power sources develop in coordination. As of the end of October 2023, the installed capacity of clean energy in Fujian Province reached 50.27 million kilowatts, accounting for 62.6% of the total installed capacity in the province. Among this, the installed capacity of offshore wind power reached 3.21 million kilowatts, ranking third in the country. It is estimated that the theoretical potential of offshore wind power in Fujian exceeds 120 million kilowatts, and with the grid connection of a batch of large-capacity offshore wind turbine units, the scale of offshore wind power grid connection will continue to expand.

The new type of power system is characterized by a “double high” (high proportion of renewable energy and high proportion of power electronic devices), which continuously raises the requirements for the safe and stable operation of the power grid. Once operational, the base will establish a wind turbine grid connection performance test and evaluation system based on ground tests, and establish related standards. It will provide efficient and reliable technical means for the grid connection tests of large-capacity offshore wind turbine units, improve the performance quality and grid-friendly level of wind turbine units, and ensure the safe and reliable operation of the grid with large-scale wind power integration. This supports the development of clean energy and contributes to the realization of the “dual carbon” goals.

Data from the National Energy Administration shows that by the end of June 2023, China’s installed capacity of renewable energy exceeded 1.3 billion kilowatts, historically surpassing coal power. Among these, wind power installations reached 389 million kilowatts, maintaining the global lead for 13 consecutive years. The State Grid Corporation of China will resolutely implement the new energy security strategy of “Four Revolutions and One Cooperation,” adhere to the corporate purpose of serving the people through the power industry, and advance the high-quality development of “One Body and Four Wings.” This approach is aimed at building an internationally leading, China-characteristic energy interconnection enterprise, powering a better life, and empowering a beautiful China.

Media Contact
Company Name: State Grid Fujian Electric Power Co., Ltd.
Contact Person: Wu Zheng
Email: Send Email
Country: China
Website: https://fjsdl.dlzbxx.com/